Brain-derived Neurotrophic Factor and Cogntive Function

Rigshospitalet

Status: Unknown

Conditions: Bodycomposition; Cognitive Dysfunction; Low-grade Inflammation; Glucose Metabolism

Study type: Observational

Funder types: Other

Identifiers

NCT01390688

H-4-2011-031

Details and patient eligibility

About

Individuals with type 2 diabetes have an increased risk of developing cognitive dysfunction followed by dementia in late life. Obesity, physical inactivity and "systemic low-grade inflammation" are strong risk factors and play a crucial role in this network of diseases.

Brain-derived Neurotrophic factor (BDNF) is produced in brain as well as several tissues outside brain eg muscle cells. Low BDNF are associated with cognitive dysfuction, obesity and type 2 diabetes.

The investigators include 200 individuals divided into three groups: 80 individuals with type 2 diabetes, 80 age and BMI-matched controls and 40 individuals with impaired glucose tolerance.

The project will test the hypothesis, that low systemic BDNF are associated with accumulation of abdominal fat, cognitive dysfunction and insulin resistence with different effect in men and women.

Full description

Methods:

200 individuals in age 40-65 years are recruited and categorized into 3 groups: 1. Type 2 Diabetes, 2. Impaired glucose Tolerance and 3. Normal Glucose Tolerance. Groups are supposed to be age and BMI-matched.

Measurements of systemic BDNF, cogntive function (memory, attention and langue), fitness, bodycomposition, glucose metabolism and systemic inflammation are done.

Multiple regression analysis are perfomed to explain variablity in cognitive function, with age, visceral fat and BDNF as explanotory varibales.

Enrollment: 200 patients

Sex: All

Ages: 40 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 40-65 years of age

Exclusion criteria

• Chronic inflammatory diseases or infectious diseaases within 3 month prior to visit
• Fasting glucose > 12 mmol/l
• Hypertension: systolic >180 mmHg and Diastolic >110 mmHg
• Intake of more than 2 oral antidiabetic drugs or any TZD drung within 3 months before recruitment

Trial design

200 participants in 3 patient groups

Type 2 Diabetes

Description:

80 individuals with type 2 Diabetes, confirmed by an OGTT, age 40-65 years, BMI \> 18.5 kg/m2 fatsing plasma glucose \< 12 mmol/l

Impaired glucose tolerance

Description:

40 individuals with impaired glucose tolerance. age 40 -65 years, BMI \> 18. 5 kg/m2

Normal glucose tolerance

Description:

80 Individuals without type 2 diabetes Age 40-65 years, BMI \>18.5 kg/m2.